RaQualia Pharma Inc. (4579.T)
JPY 377.0
(-1.31%)
JPY 377.0
(-1.31%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.9 Billion JPY | -34.85% |
| 2022 | 2.91 Billion JPY | 5.11% |
| 2021 | 2.77 Billion JPY | 150.72% |
| 2020 | 1.1 Billion JPY | -34.98% |
| 2019 | 1.7 Billion JPY | 128.74% |
| 2018 | 744.51 Million JPY | -47.54% |
| 2017 | 1.41 Billion JPY | 101.24% |
| 2016 | 705.23 Million JPY | 384.7% |
| 2015 | 145.5 Million JPY | -5.46% |
| 2014 | 153.89 Million JPY | -32.52% |
| 2013 | 228.04 Million JPY | 686.96% |
| 2012 | 28.97 Million JPY | -95.76% |
| 2011 | 684.2 Million JPY | -42.35% |
| 2010 | 1.18 Billion JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 648.58 Million JPY | 59.86% |
| 2024 Q2 | 762.46 Million JPY | 17.56% |
| 2023 Q4 | 405.7 Million JPY | -15.72% |
| 2023 FY | 1.9 Billion JPY | -34.85% |
| 2023 Q1 | 370.49 Million JPY | -63.45% |
| 2023 Q2 | 643.59 Million JPY | 73.71% |
| 2023 Q3 | 481.4 Million JPY | -25.2% |
| 2022 Q1 | 339.27 Million JPY | -70.58% |
| 2022 FY | 2.91 Billion JPY | 5.11% |
| 2022 Q4 | 1.01 Billion JPY | 121.76% |
| 2022 Q3 | 457.12 Million JPY | -58.74% |
| 2022 Q2 | 1.1 Billion JPY | 226.55% |
| 2021 Q1 | 655.61 Million JPY | 22.83% |
| 2021 Q2 | 665.05 Million JPY | 1.44% |
| 2021 Q4 | 1.15 Billion JPY | 281.23% |
| 2021 Q3 | 302.47 Million JPY | -54.52% |
| 2021 FY | 2.77 Billion JPY | 150.72% |
| 2020 Q3 | 200.81 Million JPY | -19.42% |
| 2020 FY | 1.1 Billion JPY | -34.98% |
| 2020 Q2 | 249.2 Million JPY | 101.72% |
| 2020 Q1 | 123.53 Million JPY | -87.58% |
| 2020 Q4 | 533.75 Million JPY | 165.8% |
| 2019 FY | 1.7 Billion JPY | 128.74% |
| 2019 Q3 | 162.53 Million JPY | -17.85% |
| 2019 Q4 | 994.8 Million JPY | 512.07% |
| 2019 Q1 | 347.79 Million JPY | 64.27% |
| 2019 Q2 | 197.83 Million JPY | -43.12% |
| 2018 FY | 744.51 Million JPY | -47.54% |
| 2018 Q4 | 211.72 Million JPY | 143.45% |
| 2018 Q1 | 396.37 Million JPY | -51.26% |
| 2018 Q2 | 49.45 Million JPY | -87.52% |
| 2018 Q3 | 86.96 Million JPY | 75.87% |
| 2017 Q1 | 417.79 Million JPY | 526.98% |
| 2017 FY | 1.41 Billion JPY | 101.24% |
| 2017 Q4 | 813.18 Million JPY | 470.89% |
| 2017 Q3 | 142.44 Million JPY | 211.16% |
| 2017 Q2 | 45.77 Million JPY | -89.04% |
| 2016 Q2 | 12.5 Million JPY | -97.93% |
| 2016 FY | 705.23 Million JPY | 384.7% |
| 2016 Q1 | 604.6 Million JPY | 591.22% |
| 2016 Q3 | 21.5 Million JPY | 72.0% |
| 2016 Q4 | 66.63 Million JPY | 209.93% |
| 2015 Q3 | 13.03 Million JPY | -59.9% |
| 2015 FY | 145.5 Million JPY | -5.46% |
| 2015 Q1 | 12.5 Million JPY | -65.12% |
| 2015 Q2 | 32.5 Million JPY | 160.0% |
| 2015 Q4 | 87.46 Million JPY | 571.24% |
| 2014 FY | 153.89 Million JPY | -32.52% |
| 2014 Q4 | 35.83 Million JPY | 59.26% |
| 2014 Q3 | 22.5 Million JPY | -68.97% |
| 2014 Q2 | 72.5 Million JPY | 214.37% |
| 2014 Q1 | 23.06 Million JPY | -79.27% |
| 2013 Q1 | 30.91 Million JPY | 6.67% |
| 2013 Q4 | 111.27 Million JPY | 223.81% |
| 2013 Q3 | 34.36 Million JPY | -33.27% |
| 2013 Q2 | 51.49 Million JPY | 66.6% |
| 2013 FY | 228.04 Million JPY | 686.96% |
| 2012 Q3 | - JPY | 0.0% |
| 2012 Q1 | - JPY | -100.0% |
| 2012 FY | 28.97 Million JPY | -95.76% |
| 2012 Q4 | 28.97 Million JPY | 0.0% |
| 2012 Q2 | - JPY | 0.0% |
| 2011 Q3 | 62.96 Million JPY | 0.0% |
| 2011 FY | 684.2 Million JPY | -42.35% |
| 2011 Q4 | 19.15 Million JPY | -69.58% |
| 2011 Q1 | 602.08 Million JPY | 0.0% |
| 2011 Q2 | - JPY | -100.0% |
| 2010 FY | 1.18 Billion JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 4.77 Billion JPY | 60.143% |
| PRISM BioLab Co.,LTD | 112.92 Million JPY | -1583.582% |
| GNI Group Ltd. | 26.01 Billion JPY | 92.691% |
| Linical Co., Ltd. | 12.3 Billion JPY | 84.553% |
| Trans Genic Inc. | 13.08 Billion JPY | 85.469% |
| MEDINET Co., Ltd. | 661.54 Million JPY | -187.389% |
| Soiken Holdings Inc. | 5.15 Billion JPY | 63.144% |
| Cytori Cell Research Institute, Inc. | 1.56 Billion JPY | -21.842% |
| AnGes, Inc. | 152.98 Million JPY | -1142.738% |
| OncoTherapy Science, Inc. | 610.11 Million JPY | -211.612% |
| Nxera Pharma Co., Ltd. | 12.76 Billion JPY | 85.107% |
| Immuno-Biological Laboratories Co., Ltd. | 816.7 Million JPY | -132.79% |
| NanoCarrier Co., Ltd. | 135.5 Million JPY | -1303.018% |
| Carna Biosciences, Inc. | 1.62 Billion JPY | -16.933% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 428.36 Million JPY | -343.829% |
| Chiome Bioscience Inc. | 682.46 Million JPY | -178.579% |
| Kidswell Bio Corporation | 2.43 Billion JPY | 21.801% |
| PeptiDream Inc. | 28.71 Billion JPY | 93.378% |
| Oncolys BioPharma Inc. | 63.03 Million JPY | -2915.962% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | - JPY | -Infinity% |
| Healios K.K. | 121 Million JPY | -1471.241% |
| BrightPath Biotherapeutics Co., Ltd. | 72 Thousand JPY | -2640458.333% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 39.88 Million JPY | -4666.47% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 4.51 Billion JPY | 57.85% |
| FunPep Company Limited | 530 Thousand JPY | -358617.358% |
| Kringle Pharma, Inc. | 69.25 Million JPY | -2645.418% |
| Stella Pharma Corporation | 269.49 Million JPY | -605.479% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | 316.81 Million JPY | -500.093% |
| Cuorips Inc. | 23.1 Million JPY | -8129.599% |
| K Pharma,Inc. | 1 Billion JPY | -90.12% |
| Takara Bio Inc. | 43.5 Billion JPY | 95.63% |
| ReproCELL Incorporated | 2.42 Billion JPY | 21.659% |
| PhoenixBio Co., Ltd. | 1.71 Billion JPY | -10.837% |
| StemCell Institute Inc. | 2.48 Billion JPY | 23.375% |
| Japan Tissue Engineering Co., Ltd. | 2.51 Billion JPY | 24.381% |
| CellSeed Inc. | 190.13 Million JPY | -899.927% |